Table 1.
Antineoplastic Drug | Metabolism | Interaction | Ref. |
---|---|---|---|
Etoposide | Metabolized by CYP3A4 | Decrease etoposide exposure (area under the concentration time curve (AUC) 26.2% ↓) | [39] |
Nilotinib | Metabolized by CYP3A4 | Increase nilotinib exposure (Cmax 60% ↑, AUC 29% ↑) No increase in adverse events |
[40] |
Sunitinib | Metabolized by CYP3A4 | Increase sunitinib exposure (Cmax 10.9% ↑, AUC 11% ↑) No increase in toxicity |
[41] |